Novartis Venture Fund
Investor profile
Venture capital
Also recorded as: Novartis
Deals
29
distinct rounds
Companies
22
backed
Active span
2000–2025
26 yrs
Total round €
€1.3B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Forbion4
- EQT Life Sciences3
- Life Sciences Partners3
- LODH Immunology Fund3
- M Ventures3
- Pfizer Ventures3
- Ysios Capital3
- Abingworth LLP2
- Advent Venture Partners2
- Aravis Ventures2
- Asabys Partners2
- BioGeneration Ventures2
- Brandon Capital2
- Gilde Healthcare2
- HealthCap2
- Index Ventures2
- Merifin Capital2
- New Enterprise Associates2
- Novo A2
- Omega Funds2
- Pictet2
- Roche Venture Fund2
- S2
- Schroders Capital2
- Sofinnova Partners2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| SpliceBio | Spain | 2 | €168M |
| Merus | Netherlands | 3 | €126M |
| Anaveon | Switzerland | 1 | €106M |
| NovImmune | Switzerland | 3 | €104M |
| Artios | UK | 1 | €99M |
| Citryll | Netherlands | 1 | €85M |
| F2G | UK | 2 | €82M |
| GenSight Biologics | France | 2 | €65M |
| NRG Therapeutics | UK | 1 | €58M |
| CatalYm | Germany | 1 | €50M |
| Oculis | Switzerland | 1 | €48M |
| FoRx Therapeutics | Switzerland | 1 | €43M |
| Vivet Therapeutics | France | 1 | €38M |
| Epsilogen | UK | 1 | €37M |
| Atlas Genetics | UK | 1 | €32M |
| Enterprise Therapeutics | UK | 1 | €30M |
| Ayala Pharmaceuticals | Israel | 1 | €26M |
| Inflazome | Ireland | 1 | €15M |
| MyoPowers Medical Technologies | Switzerland | 1 | €15M |
| Deciphex | Ireland | 1 | €11M |
| Rappta Therapeutics | Finland | 1 | €9.0M |
| LoQus23 Therapeutics | UK | 1 | €8.3M |